Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$72.67
Open:$72.72
Day's Low:$72.63
Day's High:$72.72
Bid / Ask:-
Market Cap:11.41B
Enterprise Value:11.42B
52-Week Range
52-Week Low:$43.20
52-Week High:$72.75
Current position in 52-week range
52w Low-52w High
50-Day Avg:$72.46
200-Day Avg:$63.17
Volume
Volume Today:3,511,852
Avg Volume (3m):2,801,850
Avg Volume (10d):2,818,480
52-Week Change:+18.94%
vs S&P 500, 52 weeks:-
Beta:1.28
Valuation Multiples
P/E (trailing):63.18
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 24, 2026. The P/E is the price divided by that EPS.
P/E (forward):31.44
PEG Ratio:2.17
Price / Book:5.38
Price / Sales (TTM):9.39
EV / Revenue:9.40
EV / EBITDA:34.18
Dividends
Current yield:0.44%
Annual Dividend Rate:$0.32
Dividend Trailing:$0.32
Yield Trailing:0.44%
5-Year Avg Yield:0.43%
Payout Ratio:27.59%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):1.22B
Gross Profit:804.88M
EBITDA:334.11M
Net Income (TTM):181.84M
Rev Growth (YoY):+1.30%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$1.15
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 24, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$2.31
Revenue Per Share:$7.79
Cash Per Share:-
Book Value:$13.51
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:265.48M
Total Debt:289.09M
Net Debt (Debt - Cash):23.61M
Debt / Equity:13.71%
Current Ratio:4.55
Quick Ratio:2.95
Cash Flows
Operating Cash Flow:292.07M
Free Cash Flow (FCF):229.65M
FCF Yield (FCF / Market Cap):-
Enterprise Value:11.42B
EV / Revenue:9.40
EV / EBITDA:34.18
Profitability
ROE (Return on Equity):9.03%
ROA (Return on Assets):6.67%
P/E (trailing):63.18
P/E (forward):31.44
Price / Book:5.38
PEG Ratio:2.17
52-Week Change:+18.94%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$1.15
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 24, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$2.31
P/E (forward):31.44
PEG Ratio:2.17
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$7.79
Cash Per Share:-
Book Value:$13.51
Cash Flows (TTM)
Free Cash Flow:229.65M
Operating Cash Flow:292.07M
EBITDA:334.11M
Total Revenue (TTM):1.22B
Net Income (TTM):181.84M
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:157,055,564
Float (free shares):156,147,056
Short interest (shares):7,552,208
Short % of float:-
Short Ratio (days to cover):2.42
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Bio-Techne Corporation (TECH) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer
50
884,350
Mr. William A. Geist
President of Protein Sciences Segment
56
1.06M
Mr. Steven C. Crouse
President of Diagnostics & Spatial Biology Segment
52
667,957
Dr. Gary J. Latham Ph.D.
VP & CTO
-
-
Mr. David Clair C.F.A.
Vice President of Investor Relations
-
-
Mr. Martin Wirtz
Senior Vice President of Strategy & Corporate Development
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
Bio-Techne Corporation (TECH) — Healthcare — Biotechnology. TECH is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, TECH has returned +24.0% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
TECH ranks 204 of 461 on today's multifactor score, and 27 of the 55 Healthcare companies that score. Its strongest factor is growth (Z 0.32, ranked 99 of 489); its weakest is value (Z -0.64, ranked 430 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Frequently asked questions about Bio-Techne (TECH)
When does Bio-Techne report earnings?
According to Nasdaq's public calendar (checked on Nov 4, 2026), Bio-Techne will report its next earnings on Nov 4, 2026, with no time announced. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 12 before the open (SEC filings through Aug 12, 2026). TECH earnings dates and times, quarter by quarter →
What is Bio-Techne's P/E ratio?
Bio-Techne's P/E (price over earnings per share for the last twelve months) is 63.2 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jun 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Bio-Techne is above its sector median. Healthcare stocks, company by company →
Where does Bio-Techne rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Bio-Techne ranks 204 of 461, and 27 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Bio-Techne insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of Bio-Techne shares from August 2025 through Nov 3, 2026. The latest sale was on May 8, 2026, by a director, for $320k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 4 sales by directors, officers and large shareholders. All TECH insider trades →
Does Bio-Techne pay a dividend?
Yes. Its dividend yield is 0.44% at the Nov 3, 2026 close (annual dividend of $0.32 per share). The latest recorded ex-dividend date is Aug 24, 2026.
What sector is Bio-Techne in, and which index?
Bio-Techne is classified in the Healthcare sector (industry: Biotechnology), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.